OverviewSuggest Edit

OptiNose develops nasal drug delivery technologies and novel combination drug/device therapies. The drug delivery technologies are based upon a unique and patent-protected principal Bi-Directional Delivery which allows drugs to be more efficiently delivered to the nasal cavity. By applying the Company's drug delivery technology, most of the dose is deposited beyond the nasal valve in the upper posterior two-thirds of the nasal cavity, unlike traditional devices.

The OptiNose delivery devices have high dose reproducibility and avoid drug deposition to the lungs. In summary, the technology fulfills the ideal requirements for nasal drug delivery. Clinical trials have shown the devices can provide a faster onset of action, greater effect with a lower dose and reduced side effects.

TypePublic
Founded2000
HQMorrisville, US
Websiteoptinose.com

Latest Updates

Employees (est.) (Mar 2019)102(+31%)
Job Openings12
Revenue (FY, 2018)$7.1 M
Share Price (Dec 2019)$8.5 (+3%)

Key People/Management at OptiNose

Peter Miller

Peter Miller

CEO
Ramy Mahmoud

Ramy Mahmoud

President
Per Djupesland

Per Djupesland

CSO
Show more

OptiNose Office Locations

OptiNose has offices in Morrisville, Oslo and Park
Morrisville, US (HQ)
1020 Stony Hill Rd #300
Oslo, NO
Gaustadalléen
Park, GB
Hunts Rise
Show all (3)

OptiNose Financials and Metrics

OptiNose Revenue

OptiNose's revenue was reported to be $7.07 m in FY, 2018
USD

Revenue (Q3, 2019)

12.4m

Gross profit (Q3, 2019)

11.0m

Gross profit margin (Q3, 2019), %

88.8%

Net income (Q3, 2019)

(28.8m)

EBIT (Q3, 2019)

(19.8m)

Market capitalization (6-Dec-2019)

352.2m

Closing stock price (6-Dec-2019)

8.5

Cash (30-Sept-2019)

125.5m

EV

301.0m
OptiNose's current market capitalization is $352.2 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Revenue

85.0k47.5m7.1m

Revenue growth, %

55782%

Cost of goods sold

1.6m

Gross profit

5.5m
Quarterly
USDQ3, 2016Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

865.0k1.3m1.9m4.5m6.7m12.4m

Cost of goods sold

200.0k351.0k319.0k738.0k1.1m1.4m

Gross profit

665.0k923.0k1.6m3.7m5.6m11.0m

Gross profit Margin, %

77%72%83%84%84%89%
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Cash

15.2m36.8m234.9m201.0m

Accounts Receivable

448.0k384.0k46.0k2.3m

Prepaid Expenses

1.3m2.2m

Inventories

2.0m7.1m
Quarterly
USDQ3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

49.4m209.8m245.0m221.5m171.3m144.0m125.5m

Accounts Receivable

231.0k2.0m3.7m2.9m5.8m9.3m10.7m

Prepaid Expenses

438.0k1.4m2.2m1.9m3.8m3.0m3.2m

Inventories

241.0k3.6m5.0m7.0m5.7m4.3m4.4m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(28.3m)22.6m(48.9m)(106.7m)

Depreciation and Amortization

164.0k539.0k

Inventories

(2.0m)(4.7m)

Accounts Payable

450.0k(130.0k)392.0k3.2m
Quarterly
USDQ3, 2016Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

28.2m(29.4m)(30.6m)(55.2m)(80.3m)(28.9m)(56.3m)(85.1m)

Depreciation and Amortization

104.0k156.0k172.0k325.0k269.0k592.0k878.0k

Inventories

(241.0k)(1.5m)(2.7m)(4.7m)1.4m2.8m2.8m

Accounts Payable

(524.0k)(574.0k)3.7m2.9m2.6m584.0k(4.3m)(1.9m)
USDY, 2019

EV/EBIT

-15.2 x

EV/CFO

-4.1 x

Debt/Equity

1.7 x

Debt/Assets

0.5 x

Financial Leverage

3.4 x
Show all financial metrics

OptiNose Operating Metrics

Jun, 2017

Patents (US)

43

Patents Pending (US)

35

Trademarks (US)

3
Show all operating metrics

OptiNose Online and Social Media Presence

Embed Graph

OptiNose News and Updates

Optinose to Report Second Quarter 2019 Financial Results and Corporate Updates on August 12, 2019

Conference Call and Webcast Scheduled for Monday, August 12 at 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for Monday, August 12 at 4:30 p.m. Eastern Time

Optinose Named a 2019 Best Place to Work by Philadelphia Business Journal

YARDLEY, Pa., June 19, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the Company has been named one of the Philadelphia Business Journal’s “Best Places to Work” for 2…

Optinose Reports First Quarter 2019 Financial Results and Recent Operational Highlights

Company reports first quarter 2019 total revenues of $4.5 million.

Optinose to Report First Quarter 2019 Financial Results and Corporate Updates on May 9, 2019

Conference Call and Webcast Scheduled for Thursday, May 9 at 8:00 a.m. Eastern Time Conference Call and Webcast Scheduled for Thursday, May 9 at 8:00 a.m. Eastern Time

Optinose Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Highlights

Company reports fourth quarter and full year 2018 net XHANCE revenue of $3.0 million and $7.1 million

Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference

YARDLEY, Pa., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present at the 2018 Prescriptions for Success Healthcar…
Show more

OptiNose Blogs

Optinose to Present at the Piper Jaffray 31st Annual Healthcare Conference

Optinose to Present at the Piper Jaffray 31st Annual Healthcare Conference Content Import Tue, 11/26/2019 - 16:01 Optinose to Present at the Piper Jaffray 31st Annual Healthcare Conference November 26, 2019 at 4:01 PM EST This release is a backfill from a News…

Optinose Announces Pricing of Public Offering of Common Stock

YARDLEY, Pa. , Nov. 21, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public

Optinose Announces Proposed Public Offering of Common Stock

Optinose Announces Proposed Public Offering of Common Stock Content Import Wed, 11/20/2019 - 16:00 Optinose Announces Proposed Public Offering of Common Stock November 20, 2019 at 4:00 PM EST This release is a backfill from a News Wire General …

Optinose Reports Third Quarter 2019 Financial Results and Recent Operational Highlights

XHANCE net revenue grew 30% to $8.7 million from second to third quarter 2019 XHANCE prescriptions increased 27% from second to third quarter 2019 Company expects XHANCE net revenues for 2019 to be in the range of $30 - $33 million Conference call and webcast to be held today at 4:30 p.m.

Optinose to Report Third Quarter 2019 Financial Results and Corporate Updates on November 12, 2019

Optinose to Report Third Quarter 2019 Financial Results and Corporate Updates on November 12, 2019 Content Import Fri, 11/01/2019 - 08:01 Optinose to Report Third Quarter 2019 Financial Results and Corporate Updates on November 12, 2019 November 1, 2019 at 8:00 AM EDT …

Optinose Appoints Michael Richardson to New Position of Vice President, Business Development

YARDLEY, Pa. , Oct. 04, 2019 (GLOBE NEWSWIRE) --   Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported the creation of a new role of Vice President, Business Development and appointment of Michael
Show more

OptiNose Frequently Asked Questions

  • When was OptiNose founded?

    OptiNose was founded in 2000.

  • Who are OptiNose key executives?

    OptiNose's key executives are Peter Miller, Ramy Mahmoud and Per Djupesland.

  • How many employees does OptiNose have?

    OptiNose has 102 employees.

  • What is OptiNose revenue?

    Latest OptiNose annual revenue is $7.1 m.

  • What is OptiNose revenue per employee?

    Latest OptiNose revenue per employee is $69.3 k.

  • Who are OptiNose competitors?

    Competitors of OptiNose include Avedro, PhaseBio Pharmaceuticals and Charles River Laboratories International.

  • Where is OptiNose headquarters?

    OptiNose headquarters is located at 1020 Stony Hill Rd #300, Morrisville.

  • Where are OptiNose offices?

    OptiNose has offices in Morrisville, Oslo and Park.

  • How many offices does OptiNose have?

    OptiNose has 3 offices.